Exploring Grade Classification in Patients With Neuroendocrine Tumors

Opinion
Video

Panelists discuss how accurate grading and classification of neuroendocrine tumors is crucial for determining prognosis and treatment strategies, focusing on key histopathological features.

Recent Videos
3 experts are featured in this series.
3 experts are featured in this series.
4 experts are featured in this series.
6 experts are featured in this series.
Related Content
Phase 3 data show that ITM-11 produced favorable safety results among patients with gastroenteropancreatic neuroendocrine tumors.

Investigational Agent Improves PFS Vs Everolimus in Grade 1/2 GI NETs

Russ Conroy
January 29th 2025
Article

Phase 3 data show that ITM-11 produced favorable safety results among patients with gastroenteropancreatic neuroendocrine tumors.

Oncologists discuss data from the NETTER-1 and NETTER-2 trials and the extent to which they support the applicability of 177Lu-dotatate in NETs.

Determining Suitable Radioligand Therapy Use in Neuroendocrine Tumors

Natasha Bahri, MD, MS;Daneng Li, MD
December 30th 2024
Podcast

Oncologists discuss data from the NETTER-1 and NETTER-2 trials and the extent to which they support the applicability of 177Lu-dotatate in NETs.

Investigators are assessing treatment with ELC-100 among patients with pancreatic neuroendocrine tumors as part of a phase 1/2 trial.

FDA Grants Orphan Drug Designation to ELC-100 in Pancreatic NETs

Russ Conroy
January 13th 2025
Article

Investigators are assessing treatment with ELC-100 among patients with pancreatic neuroendocrine tumors as part of a phase 1/2 trial.

FDA acceptance is based on phase 3 CABINET trial results, with cabozantinib showing a PFS improvement in patients with pancreatic neuroendocrine tumors.

FDA Accepts sNDA for Cabozantinib in Pancreatic Neuroendocrine Tumors

Roman Fabbricatore
August 8th 2024
Article

FDA acceptance is based on phase 3 CABINET trial results, with cabozantinib showing a PFS improvement in patients with pancreatic neuroendocrine tumors.

Data from 2 NETTER trials support lutetium Lu 177 dotatate's approval in somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.

FDA Approves Lutetium Lu 177 Dotatate in Pediatric SSTR+ GEP-NETs

Ariana Pelosci
April 23rd 2024
Article

Data from 2 NETTER trials support lutetium Lu 177 dotatate's approval in somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.

Findings from a phase 2 trial support the potential survival benefit of BXCL701 plus pembrolizumab in patients with small cell neuroendocrine prostate cancer.

BXCL701 Earns FDA FTD in Small Cell Neuroendocrine Prostate Cancer

Russ Conroy
February 12th 2024
Article

Findings from a phase 2 trial support the potential survival benefit of BXCL701 plus pembrolizumab in patients with small cell neuroendocrine prostate cancer.